A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Anitocabtagene Autoleucel, Bortezomib (BTZ), Carfilzomib (Kyprolis), Daratumumab, Dexamethasone, Pomalidomide (POM)(CC-4047)

Principal Investigator(s):

Biltibo, Eden

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

06-23-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTCTT23578

National Clinical Trial ID:

NCT06413498

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available